Technetium Tc 99m tilmanocept for injection

The first and only agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsy, Lymphoaim® provides accurate and precise lymph node identification enabling onco-surgeons make appropriate decisions in patients with breast cancer, head & neck cancer and melanomas.

Globally the product is approved as Lymphoseek

  Awaiting DCGI approval

For more information on LymphoAim®
Please refer https://www.navidea.com/ or contact your local sales representative or email us at info@sayretherapeutics.com